Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shu Jin San (specifically Lyu's Shu Jin San in the provided context) is a Traditional Chinese Medicine (TCM) herbal formulation used for the treatment of musculoskeletal disorders, particularly rheumatoid arthritis (RA) characterized by cold-dampness syndrome. Developed and utilized by the Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, it is often administered as an adjunctive therapy alongside conventional disease-modifying antirheumatic drugs (DMARDs) like methotrexate. The formula aims to alleviate joint pain, reduce swelling, and improve mobility by relaxing the tendons and expelling cold and dampness according to TCM principles. As a complex herbal mixture, it likely exerts its effects through a multi-target approach involving the modulation of inflammatory cytokines and immune pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shu Jin San.